Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Serum Cytokine Levels of Systemic Lupus Erythematosus Patients in the Presence of Concomitant Cardiovascular Diseases

Author(s): Mark M. Melamud, Evgeny A. Ermakov, Anastasiia S. Boiko, Daria A. Parshukova, Alexey E. Sizikov, Svetlana A. Ivanova, Georgy A. Nevinsky and Valentina N. Buneva*

Volume 22, Issue 8, 2022

Published on: 23 May, 2022

Page: [852 - 861] Pages: 10

DOI: 10.2174/1871530322666220304214512

Price: $65

Abstract

Background: Systemic lupus erythematosus (SLE) is known to be associated with an increased risk of cardiovascular diseases (CVD). SLE patients suffer from CVD 3.5 times more often than healthy people. Cytokine-mediated inflammation is actively involved in the development of cardiovascular pathology.

Objective: Here, we analyzed serum levels of nine cytokines of steroids-treated SLE patients depending on the presence of concomitant CVD.

Methods: The levels of interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-10, IL-21, tumor necrosis factor α (TNFα), B-cell activating factor (BAFF), and a proliferation-inducing ligand (APRIL) were analyzed using multiplex immunoassay.

Results: In the total group of SLE patients (n=29), the concentrations of IL-6 and IL-10 were higher, and the APRIL level decreased compared to healthy donors (n=39, p<0.05). The same changes were observed in the group of patients without CVD (n=15); the levels of IL-6 and IL- 10 were found to be increased, and the level of APRIL was lower than in healthy individuals (p<0.05). In the group of SLE patients with CVD (n=14), the concentrations of IL-4, IL-6, IL- 10, and TNFα were found to be increased (p<0.05). Interestingly, the levels of TNFα and BAFF in SLE patients with CVD were higher than in patients without cardiovascular pathology. Thus, TNFα and BAFF levels were significantly altered in SLE with concomitant CVD compared to SLE without CVD.

Conclusion: These findings suggest that cytokine profiles in SLE with concomitant CVD and SLE without CVD are different, which should be considered in further research with large samples.

Keywords: Systemic lupus erythematosus, cardiovascular diseases, cytokines, IL-1β, IL-4, TNFα, BAFF, APRIL.

« Previous Next »
Graphical Abstract

[1]
Dörner, T.; Furie, R. Novel paradigms in systemic lupus erythematosus. Lancet, 2019, 393(10188), 2344-2358.
[http://dx.doi.org/10.1016/S0140-6736(19)30546-X] [PMID: 31180031]
[2]
Kaul, A.; Gordon, C.; Crow, M.K.; Touma, Z.; Urowitz, M.B.; van Vollenhoven, R.; Ruiz-Irastorza, G.; Hughes, G. Systemic lupus erythematosus. Nat. Rev. Dis. Primers, 2016, 2(1), 16039.
[http://dx.doi.org/10.1038/nrdp.2016.39] [PMID: 27306639]
[3]
Barber, M.R.W.; Drenkard, C.; Falasinnu, T.; Hoi, A.; Mak, A.; Kow, N.Y.; Svenungsson, E.; Peterson, J.; Clarke, A.E.; Ramsey-Goldman, R. Global epidemiology of systemic lupus erythematosus. Nat. Rev. Rheumatol., 2021, 17(9), 515-532.
[http://dx.doi.org/10.1038/s41584-021-00668-1] [PMID: 34345022]
[4]
Laustrup, H.; Voss, A.; Green, A.; Junker, P. Occurrence of systemic lupus erythematosus in a Danish community: An 8-year prospective study. Scand. J. Rheumatol., 2009, 38(2), 128-132.
[http://dx.doi.org/10.1080/03009740802419073] [PMID: 19117248]
[5]
Rees, F.; Doherty, M.; Grainge, M.; Davenport, G.; Lanyon, P.; Zhang, W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann. Rheum. Dis., 2016, 75(1), 136-141.
[http://dx.doi.org/10.1136/annrheumdis-2014-206334] [PMID: 25265938]
[6]
Pons-Estel, G.J.; Alarcón, G.S.; Scofield, L.; Reinlib, L.; Cooper, G.S. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum., 2010, 39(4), 257-268.
[http://dx.doi.org/10.1016/j.semarthrit.2008.10.007] [PMID: 19136143]
[7]
Aviña-Zubieta, J.A.; To, F.; Vostretsova, K.; De Vera, M.; Sayre, E.C.; Esdaile, J.M. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: A general population-based study. Arthritis Care Res. (Hoboken), 2017, 69(6), 849-856.
[http://dx.doi.org/10.1002/acr.23018] [PMID: 28129475]
[8]
Tselios, K.; Gladman, D.D.; Su, J.; Ace, O.; Urowitz, M.B. Evolution of risk factors for atherosclerotic cardiovascular events in systemic lupus erythematosus: A longterm prospective study. J. Rheumatol., 2017, 44(12), 1841-1849.
[http://dx.doi.org/10.3899/jrheum.161121] [PMID: 29093154]
[9]
Barbhaiya, M.; Feldman, C.H.; Chen, S.K.; Guan, H.; Fischer, M.A.; Everett, B.M.; Costenbader, K.H. Comparative risks of cardiovascular disease in patients with systemic lupus erythematosus, diabetes mellitus, and in general medicaid recipients. Arthritis Care Res. (Hoboken), 2020, 72(10), 1431-1439.
[http://dx.doi.org/10.1002/acr.24328] [PMID: 32475049]
[10]
Talaat, R.M.; Mohamed, S.F.; Bassyouni, I.H.; Raouf, A.A. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine, 2015, 72(2), 146-153.
[http://dx.doi.org/10.1016/j.cyto.2014.12.027] [PMID: 25647269]
[11]
Svenungsson, E.; Fei, G.Z.; Jensen-Urstad, K.; de Faire, U.; Hamsten, A.; Frostegard, J. TNF-alpha: A link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus, 2003, 12(6), 454-461.
[http://dx.doi.org/10.1191/0961203303lu412oa] [PMID: 12873047]
[12]
Suponitskya, E.V.; Alexandrova, E.N.; Nasonov, E.L. Clinical significance of BAFF/BLyS and APRIL in systemic lupus erythematosus and rheumatoid arthritis. Rheumatol. Sci. Pract., 2014, 52(5), 545-552.
[http://dx.doi.org/10.14412/1995-4484-2014-545-552]
[13]
Cutolo, M.; Sulli, A.; Villaggio, B.; Seriolo, B.; Accardo, S. Relations between steroid hormones and cytokines in rheumatoid arthritis and systemic lupus erythematosus. Ann. Rheum. Dis., 1998, 57(10), 573-577.
[http://dx.doi.org/10.1136/ard.57.10.573] [PMID: 9893566]
[14]
Wei, L.; MacDonald, T.M.; Walker, B.R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann. Intern. Med., 2004, 141(10), 764-770.
[http://dx.doi.org/10.7326/0003-4819-141-10-200411160-00007] [PMID: 15545676]
[15]
Chan, C.T.; Sobey, C.G.; Lieu, M.; Ferens, D.; Kett, M.M.; Diep, H.; Kim, H.A.; Krishnan, S.M.; Lewis, C.V.; Salimova, E.; Tipping, P.; Vinh, A.; Samuel, C.S.; Peter, K.; Guzik, T.J.; Kyaw, T.S.; Toh, B-H.; Bobik, A.; Drummond, G.R. Obligatory role for B cells in the development of angiotensin II-dependent hypertension. Hypertension, 2015, 66(5), 1023-1033.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.115.05779] [PMID: 26351030]
[16]
Ermakov, E.A.; Kabirova, E.M.; Sizikov, A.E.; Buneva, V.N.; Nevinsky, G.A. IgGs-abzymes from the sera of patients with systemic lupus erythematosus hydrolyzed miRNAs. J. Inflamm. Res., 2020, 13, 681-699.
[http://dx.doi.org/10.2147/JIR.S258558] [PMID: 33116748]
[17]
Petri, M.; Kim, M.Y.; Kalunian, K.C.; Grossman, J.; Hahn, B.H.; Sammaritano, L.R.; Lockshin, M.; Merrill, J.T.; Belmont, H.M.; Askanase, A.D.; McCune, W.J.; Hearth-Holmes, M.; Dooley, M.A.; Von Feldt, J.; Friedman, A.; Tan, M.; Davis, J.; Cronin, M.; Diamond, B.; Mackay, M.; Sigler, L.; Fillius, M.; Rupel, A.; Licciardi, F.; Buyon, J.P. OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med., 2005, 353(24), 2550-2558.
[http://dx.doi.org/10.1056/NEJMoa051135] [PMID: 16354891]
[18]
Piepoli, M.F.; Hoes, A.W.; Agewall, S.; Albus, C.; Brotons, C.; Catapano, A.L.; Cooney, M-T.; Corrà, U.; Cosyns, B.; Deaton, C.; Graham, I.; Hall, M.S.; Hobbs, F.D.R.; Løchen, M-L.; Löllgen, H.; Marques-Vidal, P.; Perk, J.; Prescott, E.; Redon, J.; Richter, D.J.; Sattar, N.; Smulders, Y.; Tiberi, M.; van der Worp, H.B.; van Dis, I.; Verschuren, W.M.M.; Binno, S. ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J., 2016, 37(29), 2315-2381.
[http://dx.doi.org/10.1093/eurheartj/ehw106] [PMID: 27222591]
[19]
Anolik, J.H. B cell biology: implications for treatment of systemic lupus erythematosus. Lupus, 2013, 22(4), 342-349.
[http://dx.doi.org/10.1177/0961203312471576] [PMID: 23553777]
[20]
Dossybayeva, K.; Abdukhakimova, D.; Poddighe, D. Basophils and systemic lupus erythematosus in murine models and human patients. Biology (Basel), 2020, 9(10), 308.
[http://dx.doi.org/10.3390/biology9100308] [PMID: 32977704]
[21]
du Toit, R.; Reuter, H.; Walzl, G.; Snyders, C.; Chegou, N.N.; Herbst, P.G.; Doubell, A.F. Toit du, R. Serum cytokine levels associated with myocardial injury in systemic lupus erythematosus. Rheumatology (Oxford), 2021, 60(4), 2010-2021.
[http://dx.doi.org/10.1093/rheumatology/keaa540] [PMID: 33221897]
[22]
Bautista, L.E.; Vera, L.M.; Arenas, I.A.; Gamarra, G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J. Hum. Hypertens., 2005, 19(2), 149-154.
[http://dx.doi.org/10.1038/sj.jhh.1001785] [PMID: 15361891]
[23]
Chen, S.K.; Barbhaiya, M.; Fischer, M.A.; Guan, H.; Yoshida, K.; Feldman, C.H.; Costenbader, K.H.; Everett, B.M. Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. Semin. Arthritis Rheum., 2019, 49(3), 389-395.
[http://dx.doi.org/10.1016/j.semarthrit.2019.06.005] [PMID: 31280938]
[24]
Puszkarska, A.; Niklas, A.; Głuszek, J.; Lipski, D.; Niklas, K. The concentration of tumor necrosis factor in the blood serum and in the urine and selected early organ damages in patients with primary systemic arterial hypertension. Medicine (Baltimore), 2019, 98(22), e15773.
[http://dx.doi.org/10.1097/MD.0000000000015773] [PMID: 31145298]
[25]
Studnicka-Benke, A.; Steiner, G.; Petera, P.; Smolen, J.S. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br. J. Rheumatol., 1996, 35(11), 1067-1074.
[http://dx.doi.org/10.1093/rheumatology/35.11.1067] [PMID: 8948291]
[26]
Agita, A.; Alsagaff, M.T. Inflammation, immunity, and hypertension. Acta Med. Indones., 2017, 49(2), 158-165.
[PMID: 28790231]
[27]
Dinh, Q.N.; Drummond, G.R.; Sobey, C.G.; Chrissobolis, S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. BioMed Res. Int., 2014, 2014, 406960.
[http://dx.doi.org/10.1155/2014/406960] [PMID: 25136585]
[28]
Ballou, S.P.; Lozanski, G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine, 1992, 4(5), 361-368.
[http://dx.doi.org/10.1016/1043-4666(92)90079-7] [PMID: 1420997]
[29]
Koyama, T.; Tsukamoto, H.; Miyagi, Y.; Himeji, D.; Otsuka, J.; Miyagawa, H.; Harada, M.; Horiuchi, T. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann. Rheum. Dis., 2005, 64(7), 1065-1067.
[http://dx.doi.org/10.1136/ard.2004.022491] [PMID: 15576416]
[30]
Stohl, W.; Metyas, S.; Tan, S-M.; Cheema, G.S.; Oamar, B.; Xu, D.; Roschke, V.; Wu, Y.; Baker, K.P.; Hilbert, D.M. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum., 2003, 48(12), 3475-3486.
[http://dx.doi.org/10.1002/art.11354] [PMID: 14673998]
[31]
Guimarães, P.M.; Scavuzzi, B.M.; Stadtlober, N.P.; Franchi Santos, L.F.D.R.; Lozovoy, M.A.B.; Iriyoda, T.M.V.; Costa, N.T.; Reiche, E.M.V.; Maes, M.; Dichi, I.; Simão, A.N.C. Cytokines in systemic lupus erythematosus: Far beyond Th1/Th2 dualism lupus: Cytokine profiles. Immunol. Cell Biol., 2017, 95(9), 824-831.
[http://dx.doi.org/10.1038/icb.2017.53] [PMID: 28649995]
[32]
Yu, H-H.; Liu, P-H.; Lin, Y-C.; Chen, W.J.; Lee, J-H.; Wang, L-C.; Yang, Y-H.; Chiang, B-L. Interleukin 4 and STAT6 gene polymorphisms are associated with systemic lupus erythematosus in Chinese patients. Lupus, 2010, 19(10), 1219-1228.
[http://dx.doi.org/10.1177/0961203310371152] [PMID: 20530519]
[33]
Elewa, E.A.; Zakaria, O.; Mohamed, E.I.; Boghdadi, G. The role of interleukins 4, 17 and interferon gamma as biomarkers in patients with Systemic Lupus Erythematosus and their correlation with disease activity. Egypt. Rheumatol., 2014, 36(1), 21-27.
[http://dx.doi.org/10.1016/j.ejr.2013.10.003]
[34]
Wong, C.K.; Ho, C.Y.; Li, E.K.; Lam, C.W. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus, 2000, 9(8), 589-593.
[http://dx.doi.org/10.1191/096120300678828703] [PMID: 11035433]
[35]
Gómez, D.; Correa, P.A.; Gómez, L.M.; Cadena, J.; Molina, J.F.; Anaya, J-M. Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor α protective? Semin. Arthritis Rheum., 2004, 33(6), 404-413.
[http://dx.doi.org/10.1016/j.semarthrit.2003.11.002] [PMID: 15190525]
[36]
Bartekova, M.; Radosinska, J.; Jelemensky, M.; Dhalla, N.S. Role of cytokines and inflammation in heart function during health and disease. Heart Fail. Rev., 2018, 23(5), 733-758.
[http://dx.doi.org/10.1007/s10741-018-9716-x] [PMID: 29862462]
[37]
Badr, E.; Assar, M.; Elshayeb, E.I.; Fath El-Bab, S.; El-Kousy, S. A preliminary study of the relation between IL-4 and hypertension in type II diabetes mellitus. Mol. Biol. Rep., 2018, 45(6), 1967-1972.
[http://dx.doi.org/10.1007/s11033-018-4349-7] [PMID: 30182172]
[38]
Peng, H.; Sarwar, Z.; Yang, X.P.; Peterson, E.L.; Xu, J.; Janic, B.; Rhaleb, N.; Carretero, O.A.; Rhaleb, N.E. Profibrotic role for interleukin-4 in cardiac remodeling and dysfunction. Hypertension, 2015, 66(3), 582-589.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.115.05627] [PMID: 26195478]
[39]
Crow, M.K.; Kirou, K.A.; Niewold, T.B. Cytokines in lupus. Dubois’ Lupus Erythematosus and Related Syndromes; Elsevier: Amstradem., 2019, pp. 137-152.
[http://dx.doi.org/10.1016/B978-0-323-47927-1.00012-8]
[40]
Held, C.; White, H.D.; Stewart, R.A.H.; Budaj, A.; Cannon, C.P.; Hochman, J.S.; Koenig, W.; Siegbahn, A.; Steg, P.G.; Soffer, J.; Weaver, W.D.; Östlund, O.; Wallentin, L. STABILITY Investigators Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: Experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial. J. Am. Heart Assoc., 2017, 6(10), e005077.
[http://dx.doi.org/10.1161/JAHA.116.005077] [PMID: 29066452]
[41]
Parissis, J.T.; Adamopoulos, S.N.; Venetsanou, K.F.; Karas, S.M.; Kremastinos, D.T. Elevated plasma amylase levels in advanced chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy: Correlation with circulating interleukin-6 activity. J. Interferon Cytokine Res., 2003, 23(6), 329-333.
[http://dx.doi.org/10.1089/107999003766628179] [PMID: 12859859]
[42]
Debrunner, M.; Schuiki, E.; Minder, E.; Straumann, E.; Naegeli, B.; Mury, R.; Bertel, O.; Frielingsdorf, J. Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin. Res. Cardiol., 2008, 97(5), 298-305.
[http://dx.doi.org/10.1007/s00392-007-0626-5] [PMID: 18491171]
[43]
Astier, A.L.; Hafler, D.A. Abnormal Tr1 differentiation in multiple sclerosis. J. Neuroimmunol., 2007, 191(1-2), 70-78.
[http://dx.doi.org/10.1016/j.jneuroim.2007.09.018] [PMID: 17936368]
[44]
Go, N.F.; Castle, B.E.; Barrett, R.; Kastelein, R.; Dang, W.; Mosmann, T.R.; Moore, K.W.; Howard, M. Interleukin 10, a novel B cell stimulatory factor: Unresponsiveness of X chromosome-linked immunodeficiency B cells. J. Exp. Med., 1990, 172(6), 1625-1631.
[http://dx.doi.org/10.1084/jem.172.6.1625] [PMID: 2124252]
[45]
Levy, Y.; Brouet, J.C. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J. Clin. Invest., 1994, 93(1), 424-428.
[http://dx.doi.org/10.1172/JCI116977] [PMID: 8282815]
[46]
Ban, L.; Zhang, J.; Wang, L.; Kuhtreiber, W.; Burger, D.; Faustman, D.L. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc. Natl. Acad. Sci. USA, 2008, 105(36), 13644-13649.
[http://dx.doi.org/10.1073/pnas.0803429105] [PMID: 18755894]
[47]
Peng, H.; Wang, W.; Zhou, M.; Li, R.; Pan, H-F.; Ye, D-Q. Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus. Clin. Rheumatol., 2013, 32(9), 1255-1266.
[http://dx.doi.org/10.1007/s10067-013-2294-3] [PMID: 23708831]
[48]
Zhang, J.; Roschke, V.; Baker, K.P.; Wang, Z.; Alarcón, G.S.; Fessler, B.J.; Bastian, H.; Kimberly, R.P.; Zhou, T. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol., 2001, 166(1), 6-10.
[http://dx.doi.org/10.4049/jimmunol.166.1.6] [PMID: 11123269]
[49]
Mende, R.; Vincent, F.B.; Kandane-Rathnayake, R.; Koelmeyer, R.; Lin, E.; Chang, J.; Hoi, A.Y.; Morand, E.F.; Harris, J.; Lang, T. Analysis of serum interleukin (IL)-1β and IL-18 in systemic lupus erythematosus. Front. Immunol., 2018, 9, 1250.
[http://dx.doi.org/10.3389/fimmu.2018.01250] [PMID: 29930551]
[50]
Terrier, B.; Costedoat-Chalumeau, N.; Garrido, M.; Geri, G.; Rosenzwajg, M.; Musset, L.; Klatzmann, D.; Saadoun, D.; Cacoub, P. Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J. Rheumatol., 2012, 39(9), 1819-1828.
[http://dx.doi.org/10.3899/jrheum.120468] [PMID: 22859347]
[51]
Huang, X.; Wu, H.; Qiu, H.; Yang, H.; Deng, Y.; Zhao, M.; Luo, H.; Zhou, X.; Xie, Y.; Chan, V.; Lau, C-S.; Lu, Q. The expression of Bcl-6 in circulating follicular helper-like T cells positively correlates with the disease activity in systemic lupus erythematosus. Clin. Immunol., 2016, 173, 161-170.
[http://dx.doi.org/10.1016/j.clim.2016.10.017] [PMID: 27818202]
[52]
Holsti, M.A.; Raulet, D.H. IL-6 and IL-1 synergize to stimulate IL-2 production and proliferation of peripheral T cells. J. Immunol., 1989, 143(8), 2514-2519.
[PMID: 2571638]
[53]
Lowenthal, J.W.; Cerottini, J.C.; MacDonald, H.R. Interleukin 1-dependent induction of both interleukin 2 secretion and interleukin 2 receptor expression by thymoma cells. J. Immunol., 1986, 137(4), 1226-1231.
[PMID: 3090144]
[54]
Numerof, R.P.; Aronson, F.R.; Mier, J.W. IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J. Immunol., 1988, 141(12), 4250-4257.
[PMID: 3143761]

Rights & Permissions Print Cite
Article Metrics
45
1
© 2024 Bentham Science Publishers | Privacy Policy